U. Minn team

University of Minnesota is one of twenty-two type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Antoinette Moran, MD, the TrialNet team at University of Minnesota is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

Our Team

Portrait photo

Antoinette Moran, MD

Portrait photo

Brandon Nathan, MD

Portrait photo

Muna Sunni, MD

Portrait photo

Shannon Beasley, NP

Portrait photo

Beth Pappenfus

Portrait photo

Janice Leschyshyn, RN

kali johnson headshot

Kali Johnson, MPH

Study Coordinator

Veronica Jones-Carr, RN

Regional Affiliates

Central Iowa Hospital Corporation
1215 Pleasant St., Ste 300 , Des Moines, 50309 United States
University of Iowa, Childrens Hospital of Iowa
25 S Grand Avenue 2160 ML , Iowa City, 52242 United States
Sanford Children's Specialty Clinic
1018 West 18th Street , Sioux Falls, 57104 United States
Sanford Research - Fargo
737 Broadway N , Fargo, 58122 United States

Research Studies

Risk Screening Risk Screening for Relatives

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Monitoring Monitoring

Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More

Prevention Study ATG Prevention Study (STOP-T1D)

TrialNet is testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes (T1D) in people ages 12 up to 35 who have a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk is defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details

Long Term Long-Term Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More

Newly Diagnosed JAK Inhibitors Newly Diagnosed Study (JAKPOT T1D)

TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details

Newly Diagnosed Tolerance Using Plasmid (TOPPLE) Study: Phase 1

TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults diagnosed with type 1 diabetes (T1D) in the past 48 months. This is a Phase 1 study, which means it is the first time this treatment is being tested for safety in people. If this study results in no safety concerns, we plan to conduct a larger study to see if this same treatment can slow down or stop T1D in people at high risk, before clinical diagnosis. More

#T1DFamily Spotlight

Meet some of our TrialNet #T1DFamily members to learn what it’s like to participate in a TrialNet clinical research study.